EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcomes of Inpatient Chemotherapy for Patients with Newly Diagnosed Extensive-Stage Small-Cell Lung Cancer

Sara N Gauthier iD, Paul Wheatley-Price iD, David J Stewart iD, Stephanie Brule, Mikaela Ney iD, Garth Nicholas, Sara M Moore

Current Oncology · 26.06.2026 · 33 (7) · 388

DOI: 10.3390/curroncol33070388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 26.06.2026. Verfasst von Sara N Gauthier und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, NOSM University, 935 Ramsey Lake Rd., Sudbury, ON P3E 2C6, Canada. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Small-cell lung cancer (SCLC) accounts for 15% of lung cancers, with 70% diagnosed at extensive-stage (ES). Systemic therapy is often considered in very unwell patients, although outcomes for inpatients with ES-SCLC are not well understood.

Methods

We reviewed patients with de novo ES-SCLC who had an inpatient medical oncology consultation at the Ottawa Hospital between 2013 and 2021. The primary endpoint was overall survival (OS). Secondary endpoints included length of stay (LOS) and tumor lysis syndrome (TLS) incidence.

Results

There were 127 patients identified. Median age was 68 years (range 50–87), 58% female, 99% had prior smoking history, 22% had brain metastases, and 64% had liver metastases. Ninety-two (72%) received chemotherapy. Median OS for treated patients was 5.9 months (95% CI, 4.5–7.3 m), and a median LOS of 13 days. Patients in the non-treatment cohort had a median OS of 14 days (95% CI, 0.2–0.7 m), a median LOS of 11 days, and 54% in-hospital death rate. TLS occurred in six of the 76 (8%) evaluated patients, all dying within 7 days of chemotherapy.

Conclusions

Chemotherapy was associated with longer survival among inpatients with ES-SCLC. TLS was rare but uniformly fatal, highlighting the need for aggressive prophylaxis among patients with identified risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsHumansFemaleMaleAgedAged, 80 and overMiddle AgedInpatientsTreatment OutcomeRetrospective Studies

Stichwörter der Autor:innen

inpatientsmall-cell lung cancertumor lysis syndrome

Autor:innen und Institutionen

  • Faculty of Medicine, NOSM University, 935 Ramsey Lake Rd., Sudbury, ON P3E 2C6, Canada.
  • Division of Medical Oncology, The Ottawa Hospital, 501 Smyth Rd., Ottawa, ON K1H 8L6, Canada.
  • Cancer Therapeutics Program, Ottawa Hospital Research Institute, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.

ORCID-Profile: Sara N Gauthier, Paul Wheatley-Price, David J Stewart, Mikaela Ney

Zitieren

APA

Gauthier, S. N., Wheatley-Price, P., Stewart, D. J., Brule, S., Ney, M., Nicholas, G., & Moore, S. M. (2026). Outcomes of Inpatient Chemotherapy for Patients with Newly Diagnosed Extensive-Stage Small-Cell Lung Cancer. Current Oncology, 33(7), 388. https://doi.org/10.3390/curroncol33070388

Vancouver

Gauthier SN, Wheatley-Price P, Stewart DJ, Brule S, Ney M, Nicholas G, et al. Outcomes of Inpatient Chemotherapy for Patients with Newly Diagnosed Extensive-Stage Small-Cell Lung Cancer. Current Oncology. 2026;33(7):388. doi:10.3390/curroncol33070388

BibTeX
@article{Gauthier2026,
  author = {Gauthier, Sara N and Wheatley-Price, Paul and Stewart, David J and Brule, Stephanie and Ney, Mikaela and Nicholas, Garth and Moore, Sara M},
  title = {Outcomes of Inpatient Chemotherapy for Patients with Newly Diagnosed Extensive-Stage Small-Cell Lung Cancer},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {7},
  pages = {388},
  doi = {10.3390/curroncol33070388}
}
Kostenlos starten →